After all the bad news that have been
going round over the outbreak of the
Ebola virus in West African countries,
Nigeria, Sierra Leone, Guinea and Liberia,
a piece of good news finally arrived some
moments ago.
Reporting online in the British journal Nature,
researchers at the Public Health Agency of
Canada announced that a prototype drug,
ZMapp, that has been urgently given to a
handful of patients with Ebola has cleared an
important test hurdle.
According to the scientists report, the drug
test results showed that ZMapp cured lab
monkeys that have been infected with the
Ebola virus disease.

It was gathered that it is a norm to experiment
drugs on animals first and then on
progressively larger groups of humans to
ensure they are safe and effective.
But, in an exceptional move, ZMapp that has
not gone through these tests has been rushed
to the outbreak in West Africa, as the lethal
disease has no cure.
According to the Canadian researchers, 18
rhesus macaque monkeys given high doses of
Ebola virus fully recovered after being given
ZMapp, even when it was administered five
days after infection.
The scientists informed that the drug reversed
dangerous symptoms such as bleeding, rashes

and high levels of enzymes in the liver.
They also stated that three “control” monkeys
that had been infected, but not treated, all
died within eight days.
It was gathered that 21 animals had been
given the so-called Kikwit strain of Ebola,
named after a location in the Democratic
Republic of Congo, the country where the
hemorrhagic fever was discovered in 1976.
But lab-dish tests indicate it can also inhibit the
strain in Guinea which has sparked the current
epidemic, the scientists said.

Meanwhile, independent experts have started
hailing the results as an encouraging first step
in the long vetting process.
They added, though, that it was still unclear
whether ZMapp worked on humans, as two
patients who have been given it have died and
two others have recovered.
“Widespread availability and use of ZMapp will
require human safety testing and licensing,
coupled with scaleup of the manufacturing
process,” cautioned David Evans, a professor of
virology at Britain’s University of Warwick.
ZMapp is being developed by Mapp
Biopharmaceutical Inc. of San Diego, California,
partly in conjunction with the US Army.
ZMapp has so far been given to seven infected
frontline workers.
Of these, two American doctors have
recovered; a Liberian doctor and a Spanish
priest have died; and a doctor and a nurse,
both Liberian, and a British nurse, who has
been flown to London from Sierra Leone, are
still in treatment.
The World Health Organisation, W.H.O, gave
the green light on August 12, saying it was
ethical to use experimental drugs in the
context of this dangerous epidemic.
Stocks of ZMapp, which is derived from
tobacco leaves and is hard to produce on a
large scale, are exhausted, the company said
on August 12.
Investigation revealed that the other main
experimental drug for the disease is TKM-Ebola,
being developed by Tekmira Pharmaceuticals
Corp. of Vancouver, Canada, under a $140-
million (105-million-euro) contract with the
Pentagon.
It is currently in a Phase I human trial, the first
step in the three-phase test process. In this
phase, a drug is evaluated on healthy non-
infected humans to see whether it is safe.
Further phases test it for safety and also
effectiveness.

According to the W.H.O, about 1,500 people
have died in Guinea, Liberia, Nigeria and Sierra
Leone since the disease emerged in West Africa
early 2014.
Six people have died in Nigeria alone since the
dreaded disease was brought to the country by
a Liberian diplomat, Patrick Sawyer on 20 July,
2014 . He later died from the disease on 25
July.

.

k

Much thanks JayBel, for bringing to light this very positive development in the urgent search for an Ebola virus cure. With the formerly experimental drug named ZMap having cured nearly a dozen humans including the now legendary American volunteer doctor and nurse flown back ill with Ebola fever to the US from Sierra Leone, a further official record attesting that every one of 18 Ebola-infected medical test monkeys has made miraculous recoveries from the deadly fever after being dosed with ZMap, is the long awaited icing on the cake.

With the healing power of the drug ZMap now documented beyond scientific doubt, the technical challenges that stand in the way of exponentially speeding up manufacturing processes for this precious chemical can now be focused upon with the intensity, international funding and unified resolve needed to arrest the global spread of this smoldering contagion ever so close to becoming a conflagration of biblical scale.

In short the human race CAN be spared from this impending mass-extinction threat called Ebola, even at this late stage of the game, IF the proven curative drug ZMap can be mass-produced no later than THREE months from the August 30th 2014 day on which these words are being typed. The consequences of failure to SWIFTLY embark on the mass-production of this species-preserving vaccine called ZMap, are, on sober reflection, too great and too terrifying to contemplate.

You're welcome bro.I just pray this Zmapp be sent over to these affected countries in large quantities...